Medicine & Life Sciences

1. Melanoma 100%
2. pembrolizumab 66%
3. Neoplasms 30%
4. Survival 23%
5. T-Lymphocytes 18%
6. Therapeutics 17%
7. Ipilimumab 16%
8. Neoplasm Metastasis 16%
9. Immunotherapy 15%
10. Drug Therapy 11%
11. Ligands 11%
12. Radiosurgery 11%
13. Safety 11%
14. Renal Cell Carcinoma 11%
15. Temozolomide 10%
16. Uveal melanoma 10%
17. Everolimus 9%
18. Bevacizumab 9%
19. Lymphoproliferative Disorders 9%
20. Progression-Free Survival 8%
21. Response Evaluation Criteria in Solid Tumors 8%
22. glucopyranosyl lipid-A 7%
23. Sex Characteristics 7%
24. Immunity 6%
25. Lung Neoplasms 6%
26. ADAM17 Protein 6%
27. Programmed Cell Death 1 Receptor 6%
28. trametinib 6%
29. B-Lymphocytes 6%
30. Cisplatin 6%
31. Carboplatin 5%
32. Lymphocytes 5%
33. Carbonic Anhydrase IX 5%
34. Confidence Intervals 5%
35. Brain Neoplasms 5%
36. Vemurafenib 5%
37. platelet-derived growth factor A 5%
38. Mantle-Cell Lymphoma 5%
39. Hematinics 5%
40. Testicular Germ Cell Tumor 5%
41. Galectins 5%
42. Extracellular Vesicles 5%
43. Death Domain Receptors 5%
44. Paclitaxel 5%
45. Immunomodulation 5%
46. Periodicity 5%
47. Antibodies 5%
48. B-Cell Chronic Lymphocytic Leukemia 5%